Circulating miRNA-192 and miR-29a as Disease Progression Biomarkers in Hepatitis C Patients with a Prevalence of HCV Genotype 3
Genes · 2023
DOI: 10.3390/genes14051056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2023. Verfasst von Amin Ullah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health and Biological Sciences, Abasyn University, Peshawar 25000, Pakistan. Hauptthemen laut MEDLINE: MicroRNAs, Hepatitis C, Circulating MicroRNA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: R&D and Fortune funding of the Medical Faculty of the University of Cologne, Higher Education Commission of Pakistan.
Abstract (Originalsprache)
MicroRNAs miR-29a and miR-192 are involved in inflammatory and fibrotic processes of chronic liver disease, and circulating miR-29a is suggested to diagnose fibrosis progression due to hepatitis C virus (HCV) infection. This study aimed to evaluate the expression profile of circulating miR-192 and 29a in a patient cohort with a high frequency of HCV genotype-3. A total of 222 HCV blood samples were collected and serum were separated. Patients were classified into mild, moderate, and severe liver injury based on their Child–Turcotte–Pugh CTP score. RNA was isolated from the serum and used for quantitative real-time PCR. The HCV genotype-3 (62%) was the predominant HCV genotype. In HCV patients, the serum miR-192 and miR-29a levels were significantly upregulated in comparison to healthy controls (p = 0.0017 and p = 0.0001, respectively). The progression rate of miR-192 and 29a in the patient group with mild was highly upregulated compared to patients with moderate and severe hepatitis infection. The ROC curve of miR-192 and miR-29a of moderate liver disease had a significant diagnostic performance compared to the other HCV-infected groups. The increase in miR-29a and miR-192 serum levels was even slightly higher in patients with HCV genotype-3 than in non-genotype-3 patients. In conclusion, serum miR-192 and miR-29a levels significantly increased during the progression of chronic HCV infection. The marked upregulation in patients with HCV genotype-3 suggests them as potential biomarkers for hepatic disease, independently of the HCV genotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health and Biological Sciences, Abasyn University, Peshawar 25000, Pakistan.
- Institute for Pathology, University of Cologne, 50923 Cologne, Germany.
- Center of Biotechnology and Microbiology, University of Peshawar, Peshawar 25000, Pakistan.
- Institute of Transfusion Medicine, University of Cologne, 50923 Cologne, Germany.
- Center of Excellence in Molecular Biology, University of the Punjab, Lahore 54000, Pakistan.
- Department of Plant Breeding and Genetics, University of the Punjab, Lahore 54000, Pakistan.
ORCID-Profile: Margarete Odenthal, Tariq Nadeem, Qurban Ali
Förderung
- R&D and Fortune funding of the Medical Faculty of the University of Cologne
- Higher Education Commission of Pakistan
Zitieren
APA
Ullah, A., Rehman, I. U., Ommer, K., Ahmed, N., Odenthal, M., Yu, X., Ahmad, J., Nadeem, T., Ali, Q., & Ahmad, B. (2023). Circulating miRNA-192 and miR-29a as Disease Progression Biomarkers in Hepatitis C Patients with a Prevalence of HCV Genotype 3. Genes. https://doi.org/10.3390/genes14051056
Vancouver
Ullah A, Rehman IU, Ommer K, Ahmed N, Odenthal M, Yu X, et al. Circulating miRNA-192 and miR-29a as Disease Progression Biomarkers in Hepatitis C Patients with a Prevalence of HCV Genotype 3. Genes. 2023. doi:10.3390/genes14051056
BibTeX
@article{Ullah2023,
author = {Ullah, Amin and Rehman, Irshad Ur and Ommer, Katharina and Ahmed, Nadeem and Odenthal, Margarete and Yu, Xiaojie and Ahmad, Jamshaid and Nadeem, Tariq and Ali, Qurban and Ahmad, Bashir},
title = {Circulating miRNA-192 and miR-29a as Disease Progression Biomarkers in Hepatitis C Patients with a Prevalence of HCV Genotype 3},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14051056}
}
EUVIMED